Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Université catholique de Louvain, Brussels, Belgium.
Nutr Rev. 2012 Nov;70(11):631-41. doi: 10.1111/j.1753-4887.2012.00526.x. Epub 2012 Sep 25.
Coenzyme Q (CoQ), a lipophilic cofactor of the electron transport chain in the mitochondria, can be synthesized endogenously or provided by food. The aim of this review is to summarize the in vitro cell culture studies, the in vivo animal studies, and the human studies investigating the impact of CoQ supplementation on the occurrence of obesity and related disorders (diabetes, hypertension, lipemia, and atherosclerosis). The antioxidative properties of CoQ have been observed in different experimental models of atherosclerosis, obesity, and diabetes. The recent discovery of the anti-inflammatory effect of CoQ, mostly described in vitro, has generated increased interest in CoQ supplementation, but it needs to be confirmed in vivo in pathological situations. CoQ intervention studies in humans failed to show reproducible effects on body weight, fat mass, or glycemia, but CoQ supplementation does seem to have an antihypertensive effect. The molecular mechanism to explain this effect has only recently been discovered.
辅酶 Q（CoQ）是线粒体电子传递链中的一种亲脂性辅助因子，可内源性合成或由食物提供。本综述的目的是总结体外细胞培养研究、体内动物研究以及人类研究，这些研究调查了 CoQ 补充对肥胖和相关疾病（糖尿病、高血压、高脂血症和动脉粥样硬化）发生的影响。CoQ 的抗氧化特性已在不同的动脉粥样硬化、肥胖和糖尿病实验模型中得到观察。CoQ 的抗炎作用最近在体外被发现，这增加了人们对 CoQ 补充的兴趣，但在病理情况下还需要在体内进行证实。CoQ 干预人类的研究未能显示出对体重、体脂肪或血糖的可重复影响，但 CoQ 补充似乎确实具有降压作用。解释这种作用的分子机制最近才被发现。
